secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-08-03T21:06:22+00:00
Accession:  0001193125-26-330804
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics files prospectus supplement for up to $200M ATM offering
---------------------------------------------------------------------------

- Filed prospectus supplement on Aug 3, 2026 to sell up to $200M of common stock.
- Shares offered under existing Controlled Equity Offering Sales Agreement with Cantor Fitzgerald.
- Prospectus supplement part of automatic shelf registration statement filed March 18, 2026.
- Legal opinion of Fenwick & West LLP filed as Exhibit 5.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/0001193125-26-330804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/d135735d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer